Infection Prevention for Multiple Myeloma Patients with Dr. Benjamin Derman

Event Description

Myeloma patients need to be vigilant due to their immunocompromised status. After fighting myeloma and achieving a remission, many patients continue to worry about other infections or diseases that might come their way. What preventions should be taken to prevent infection? How can patients enjoy a high quality of life while still being cautious or protective? Hear Dr. Derman's opinion on the subject and ask your questions.

Schedule & Agenda

12:00PM - 01:00PM
Audrey Burton-Bethkee
Audrey introduces the agenda of the event and featured speaker Dr. Benjamin Derman.
Dr. Benjamin Derman
Dr. Benjamin Derman talks about what preventions should be taken to prevent infection, and how can patients enjoy a high quality of life while still being cautious or protective.
Questions and Answers
Type your questions in the chat and we will answer them!

Speakers & Moderators

The author Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the Myeloma Crowd as the Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

The author Dr. Benjamin Derman
Dr. Benjamin Derman

Benjamin Derman, MD, specializes in hematology and oncology. Dr. Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He also diagnoses and treats cancerous conditions and uses the most innovative techniques, including CAR T-cell therapy and stem cell transplantation to deliver long-term success for his patients. Along with his clinical practice, Dr. Derman remains committed to research. Currently, he is focused on identifying strategies that can lead to a possible cure for multiple myeloma, including using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making. Dr. Derman is also investigating new methods and therapies designed to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients. His work has been published in several peer-reviewed journals, including the Journal of Immunotherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia and Lymphoma and British Journal of Haematology.

Have Any Questions?

Thank you for your interest in the event. If you have any question we would love to help! Just send us a message below and we will get back to you as quickly as possible.


Get In Touch With Us


+1 800 709 1113



Sign up while there are spots left!

- May 25, 2022 / 12:00PM - 01:00PM EDT

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811